RESEARCH TRIANGLE PARK, N.C. — September 2, 2025 — Leads & Copy — Opus Genetics, Inc. (Nasdaq: IRD) has appointed Rob Gagnon, CPA, MBA, as Chief Financial Officer. Gagnon brings over two decades of financial and operational leadership experience in public and private biotech companies.
Gagnon has raised over $2 billion in capital and guided companies through IPOs, clinical development, commercial launches, and M&A.
According to George Magrath, MD, CEO of Opus Genetics, Gagnon’s experience will be invaluable as the company advances its clinical pipeline. Gagnon previously served as CFO at Remix Therapeutics and Verastem Oncology, and held senior finance roles at Harvard Bioscience, Clean Harbors, and Biogen.
Gagnon holds an MBA from MIT Sloan School of Management and a BA in Accounting from Bentley College.
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and small molecule therapies for other ophthalmic disorders. The company’s pipeline includes gene therapies targeting Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa.
Contacts:
Investors: Jenny Kobin, Remy Bernarda, IR Advisory Solutions, ir@opusgtx.com
Media: Kimberly Ha, KKH Advisors, 917-291-5744, kimberly.ha@kkhadvisors.com
Robert Gagnon, CFO
